Q2 EPS Estimates for Immix Biopharma Raised by HC Wainwright

Immix Biopharma, Inc. (NASDAQ:IMMX) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Immix Biopharma in a report issued on Friday, May 22nd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.15) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.62) EPS.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01.

Several other equities research analysts have also recently issued reports on IMMX. Citizens Jmp reiterated a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Mizuho raised their price objective on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Morgan Stanley assumed coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Immix Biopharma Trading Up 0.7%

NASDAQ IMMX opened at $8.84 on Wednesday. Immix Biopharma has a 12 month low of $1.87 and a 12 month high of $11.61. The stock has a market cap of $480.98 million, a PE ratio of -9.61 and a beta of 0.12. The stock’s 50 day moving average is $9.41 and its 200 day moving average is $7.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP bought a new stake in Immix Biopharma during the fourth quarter worth approximately $30,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma in the 4th quarter worth approximately $56,000. Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma in the 4th quarter worth approximately $67,000. Kera Capital Partners Inc. purchased a new position in shares of Immix Biopharma in the 4th quarter worth approximately $68,000. Finally, Velan Capital Investment Management LP boosted its holdings in shares of Immix Biopharma by 40.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after purchasing an additional 10,000 shares during the period. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.